Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer

被引:7
|
作者
Witjes, J. Alfred [1 ]
Feikema, Astrid A. H. [1 ]
机构
[1] Radboudumc, Dept Urol, Nijmegen, Netherlands
来源
CANCER MANAGEMENT AND RESEARCH | 2021年 / 13卷
关键词
bladder cancer; cystectomy; trimodality treatment; oncological outcome; functional outcome; organ preservation; RADICAL CYSTECTOMY; TRANSURETHRAL RESECTION; OUTCOMES; THERAPY; CHEMOTHERAPY; GUIDELINES; SURGERY;
D O I
10.2147/CMAR.S294099
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radical cystectomy (RC) is the treatment of choice and is strongly recommended for patients with pT2-4aN0M0 bladder cancer in both the European Association of Urology (EAU) and American Urological Association (AUA) muscle-invasive bladder cancer (MIBC) guidelines. RC is a challenging operation, with significant perioperative and postoperative morbidity and mortality, having short-term complication rates between 14.4% and 21.7%, and long-term oncological survival rates ranging from 60% after 5 years to 43% after 10 years. The impact on quality of life (QoL) in patients after treatment for bladder cancer is significantly worse than in other pelvic cancers. Although RC is strongly recommended as the gold standard, there is a need for bladder-sparing options in MIBC. Attempts to improve mortality and morbidity rates after RC have been made by implementing Enhanced Recovery After Surgery (ERAS), robot-assisted RC, and sexual function-preserving techniques. None of these significantly improves QoL or functional outcome. Because of the invasiveness of RC, other therapeutic options have been evaluated. Transurethral resection of the bladder tumor (TURB) plays an important role in the diagnostic evaluation of MIBC and has also been reviewed as a curative option, although the oncological results appear inferior to RC. Furthermore, improved radiotherapy (RT) and widely used chemotherapy, both as mono therapeutic options in bladder cancer, are not as effective as radical surgery, with lower survival rates. Trimodality treatment (TMT) in bladder cancer combines TURB with chemotherapy and RT. The goal of TMT is preserving the bladder and QoL without compromising oncological outcome. A 2018 review showed no difference in overall survival rates between RC and TMT (30.9% vs 35.1%), with lower survival rates after RC than TMT in the first year of follow-up, probably due to higher postoperative mortality. For a selected group of patients, TMT is to be recommended, and it is the most favorable option out of the organ sparing strategies in MIBC.
引用
收藏
页码:7833 / 7839
页数:7
相关论文
共 50 条
  • [41] Surgical bladder preserving strategies in the treatment of muscle-invasive bladder cancer
    Kuczyk, M
    Machtens, S
    Bokemeyer, C
    Kollmannsberger, C
    Hartmann, J
    Kondoh, M
    Merseburger, A
    Jonas, U
    WORLD JOURNAL OF UROLOGY, 2002, 20 (03) : 183 - 189
  • [42] The treatment of muscle-invasive bladder cancer in geriatric patients
    Grubmueller, Bernhard
    Seitz, Christian
    Shariat, Shahrokh F.
    CURRENT OPINION IN UROLOGY, 2016, 26 (02) : 160 - 164
  • [43] Quality of Care Indicators for Muscle-Invasive Bladder Cancer
    Goossens-Laan, Catharina A.
    Kil, Paul J. M.
    Roukema, Jan A.
    Bosch, J. L. H. Ruud
    De Vries, Jolanda
    UROLOGIA INTERNATIONALIS, 2011, 86 (01) : 11 - 18
  • [44] Radical Cystectomy and Organ Preservation Treatment Modalities in Muscle-invasive Bladder Cancer
    Kadihasanoglu, Mustafa
    Aydin, Mustafa
    Karabay, Emre
    Yucetas, Ugur
    Toktas, Mahmut Gokhan
    ISTANBUL MEDICAL JOURNAL, 2016, 17 (02): : 41 - 47
  • [45] Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
    Calabro, Fabio
    Sternberg, Cora N.
    EUROPEAN UROLOGY, 2009, 55 (02) : 348 - 358
  • [46] Bladder-sparing radiotherapy for muscle-invasive bladder cancer: A survey of providers to determine barriers and enablers
    Walker, Melanie
    French, Simon D.
    Doiron, R. Christopher
    Brennan, Kelly
    Feldman-Stewart, Deb
    Siemens, D. Robert
    Mackillop, William J.
    Booth, Christopher M.
    RADIOTHERAPY AND ONCOLOGY, 2017, 125 (02) : 351 - 356
  • [47] Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer
    Broughman, James R.
    Vuong, Winston
    Mian, Omar Y.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 22 (01)
  • [48] Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives
    Hafeez, Shaista
    Huddart, Robert
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (12) : 1429 - 1443
  • [49] Organ-sparing treatment of advanced bladder cancer -: Paclitaxel as a radiosensitizer
    Mueller, Arndt-Christian
    Diestelhorst, Andrea
    Kuhnt, Thomas
    Kuehn, Reinhard
    Fornara, Paolo
    Scholz, Hans-Joerg
    Dunst, Juergen
    Zietman, Anthony Laurence
    STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 (04) : 177 - 183
  • [50] Managing muscle-invasive bladder cancer in the elderly
    Weizer, Alon Z.
    Palella, Gaetano V.
    Montgomery, Jeffrey S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (06) : 903 - 915